245 related articles for article (PubMed ID: 16459016)
1. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence.
Perrin P
Eur Urol; 2006 Mar; 49(3):418-9. PubMed ID: 16459016
[No Abstract] [Full Text] [Related]
2. Does PSA velocity predict prostate cancer in pre-screened populations?
Schröder FH; Roobol MJ; van der Kwast TH; Kranse R; Bangma CH
Eur Urol; 2006 Mar; 49(3):460-5; discussion 465. PubMed ID: 16442212
[TBL] [Abstract][Full Text] [Related]
3. [Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer].
Nutahara K; Higashihara E
Rinsho Byori; 2001 Oct; 49(10):963-6. PubMed ID: 11769472
[TBL] [Abstract][Full Text] [Related]
4. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
Kuruma H; Egawa S
Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
[TBL] [Abstract][Full Text] [Related]
5. The cautionary tale of PSA testing.
Hoffman RM; Zeliadt SB
Arch Intern Med; 2010 Jul; 170(14):1262-3. PubMed ID: 20660847
[No Abstract] [Full Text] [Related]
6. Is an improved PSA screening test in sight?
Savage L
J Natl Cancer Inst; 2007 Oct; 99(20):1503-4. PubMed ID: 17925529
[No Abstract] [Full Text] [Related]
7. PSA screening: the bottom line.
Elhilali MM
CMAJ; 2000 Mar; 162(6):791-2. PubMed ID: 10750466
[No Abstract] [Full Text] [Related]
8. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
D'Amico AV
J Clin Oncol; 2008 Feb; 26(6):823-4. PubMed ID: 18281649
[No Abstract] [Full Text] [Related]
9. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
[TBL] [Abstract][Full Text] [Related]
10. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
Rosser CJ; Parker A
J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
[No Abstract] [Full Text] [Related]
11. PSA: prostate-specific antigen, persisting scientific ambiguities.
Harv Mens Health Watch; 2009 Jul; 13(12):1-6. PubMed ID: 19718841
[No Abstract] [Full Text] [Related]
12. [The PSA test does not hold for screening. Good--but not good enough].
Holmström B; Johansson M; Bratt O; Stattin P
Lakartidningen; 2010 Feb 17-23; 107(7):436, 438-9. PubMed ID: 20384076
[No Abstract] [Full Text] [Related]
13. Prostate cancer detection: beware of the low PSA.
Haas GP
Can J Urol; 2007 Jun; 14(3):3534. PubMed ID: 17594742
[No Abstract] [Full Text] [Related]
14. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence.
Etzioni RD; Ankerst DP; Weiss NS; Inoue LY; Thompson IM
J Natl Cancer Inst; 2007 Oct; 99(20):1510-5. PubMed ID: 17925534
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
16. [The significance and limitation of prostate specific antigen in the mass screening for prostate cancer].
Imai K; Yamanaka H
Nihon Rinsho; 1998 Aug; 56(8):1994-7. PubMed ID: 9750494
[TBL] [Abstract][Full Text] [Related]
17. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
[TBL] [Abstract][Full Text] [Related]
18. [The use of prostate specific antigen in prostate cancer--prediction for treatment failure].
Egawa S
Nihon Rinsho; 2002 Dec; 60 Suppl 11():100-6. PubMed ID: 12599553
[No Abstract] [Full Text] [Related]
19. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Namba Y; Kishikawa H; Takahara S; Ichikawa Y
Prostate Cancer Prostatic Dis; 2008; 11(3):258-63. PubMed ID: 17876341
[TBL] [Abstract][Full Text] [Related]
20. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
